Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine effect on Pimodivir Pharmacokinetics in Healthy Adults
NCT03768609Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pimodivir in Influenza A (IAV) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Concentration at Day 8, Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration Time at Day 8 and 1 more. Started Dec 2018; status: completed.
02
Drugs
pimodivir
03
Conditions
Influenza A (IAV)
Beyond the preview
Go deeper on NCT03768609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03768609.